Top

Published in:

01-10-2016 | Original Article

Downregulation of paraoxonase 3 contributes to aggressive human hepatocellular carcinoma progression and associates with poor prognosis

Authors: Yuepeng Jin, Qiang Li, Junjun Qiu, Xiufen Zhao, Chunxiao Zheng, Shixu Lv, Yongyu Bai, Yunfeng Shan, Le-chi Ye

Published in: Tumor Biology | Issue 10/2016

Abstract

Paraoxonase (PON) enzymes possess antioxidant properties and protect against cardiovascular diseases. As a member of PON family, PON3 is primarily synthesized in the liver and poorly investigated. This study aimed to examine the expression of PON3 in human hepatocellular carcinoma (HCC) and investigate the clinical significance and biological function of PON3 in HCC patients. We first analyzed PON3 expression in 50 paired HCC samples (HCC tissues vs matched para-cancerous tissues) and 160 clinical HCC specimens by using immunohistochemistry (IHC). Our results showed that the expression of PON3 was downregulated in HCC and significantly associated with tumor-node-metastasis (TNM) stage, tumor size, and tumor number. Kaplan-Meier survival and Cox regression analyses showed that PON3 was an independent prognostic factor for overall survival (OS) and time to recurrence (TTR). Finally, we aimed to reveal the biological function of PON3 in HCC growth and metastasis, and our results showed that overexpression of PON3 potently inhibited growth and metastasis of HCC. Collectively, our study demonstrated that PON3 exhibited tumor-suppressive effects toward HCC and it might serve as a novel prognostic marker in HCC.

Available only for authorised users

Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed

Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–55.CrossRefPubMed

Tsoulfas G, Kawai T, Elias N, et al. Long-term experience with liver transplantation for hepatocellular carcinoma. J Gastroenterol. 2011;46:249–56.CrossRefPubMed

Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63:844–55.CrossRefPubMedPubMedCentral

Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol. 2005;23:2892–9.CrossRefPubMed

Ueno M, Uchiyama K, Ozawa S, et al. Adjuvant chemolipiodolization reduces early recurrence derived from intrahepatic metastasis of hepatocellular carcinoma after hepatectomy. Ann Surg Oncol. 2011;18:3624–31.CrossRefPubMed

Bergmeier C, Siekmeier R, Gross W. Distribution spectrum of paraoxonase activity in HDL fractions. Clin Chem. 2004;50:2309–15.CrossRefPubMed

Li HL, Liu DP, Liang CC. Paraoxonase gene polymorphisms, oxidative stress, and diseases. J Mol Med (Berl). 2003;81:766–79.CrossRef

Shih DM, Xia YR, Yu JM, et al. Temporal and tissue-specific patterns of Pon3 expression in mouse: in situ hybridization analysis. Adv Exp Med Biol. 2010;660:73–87.CrossRefPubMedPubMedCentral

10.

Précourt LP, Amre D, Denis MC, et al. The three-gene paraoxonase family: physiologic roles, actions and regulation. Atherosclerosis. 2011;214:20–36.CrossRefPubMed

11.

Reddy ST, Devarajan A, Bourquard N, et al. Is it just paraoxonase 1 or are other members of the paraoxonase gene family implicated in atherosclerosis? Curr Opin Lipidol. 2008;19:405–8.CrossRefPubMed

12.

Ng CJ, Shih DM, Hama SY, et al. The paraoxonase gene family and atherosclerosis. Free Radic Biol Med. 2005;38:153–63.CrossRefPubMed

13.

Ng CJ, Bourquard N, Hama SY, et al. Adenovirus-mediated expression of human paraoxonase 3 protects against the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2007;27:1368–74.CrossRefPubMed

14.

Reddy ST, Wadleigh DJ, Grijalva V, et al. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol. 2001;21:542–7.CrossRefPubMed

15.

Shih DM, Xia YR, Wang XP, et al. Decreased obesity and atherosclerosis in human paraoxonase 3 transgenic mice. Circ Res. 2007;100:1200–7.CrossRefPubMedPubMedCentral

16.

Mackness M, Mackness B. Human paraoxonase-1 (PON1): gene structure and expression, promiscuous activities and multiple physiological roles. Gene. 2015;567:12–21.CrossRefPubMedPubMedCentral

17.

Rajaraman P, Hutchinson A, Rothman N, et al. Oxidative response gene polymorphisms and risk of adult brain tumors. Neuro Oncol. 2008;10:709–15.CrossRefPubMedPubMedCentral

18.

Schwarzer C, Fu Z, Morita T, et al. Paraoxonase 2 serves a proapopotic function in mouse and human cells in response to the Pseudomonas aeruginosa quorum-sensing molecule N-(3-Oxododecanoyl)-homoserine lactone. J Biol Chem. 2015;290:7247–58.CrossRefPubMedPubMedCentral

19.

Witte I, Altenhöfer S, Wilgenbus P, et al. Beyond reduction of atherosclerosis: PON2 provides apoptosis resistance and stabilizes tumor cells. Cell Death Dis. 2011;2:e112.CrossRefPubMedPubMedCentral

20.

Choi JK, Choi JY, Kim DG, et al. Integrative analysis of multiple gene expression profiles applied to liver cancer study. FEBS Lett. 2004;565:93–100.CrossRefPubMed

21.

Santin AD, Zhan F, Bellone S, et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer. 2004;112:14–25.CrossRefPubMed

22.

Schweikert EM, Devarajan A, Witte I, et al. PON3 is upregulated in cancer tissues and protects against mitochondrial superoxide-mediated cell death. Cell Death Differ. 2012;19:1549–60.CrossRefPubMedPubMedCentral

23.

Jin H, Zhang Y, You H, et al. Prognostic significance of kynurenine 3-monooxygenase and effects on proliferation, migration, and invasion of human hepatocellular carcinoma. Sci Rep. 2015;5:10466.CrossRefPubMedPubMedCentral

24.

Zhu AX. Systemic treatment of hepatocellular carcinoma: dawn of a new era? Ann Surg Oncol. 2010;17:1247–56.CrossRefPubMed

25.

Siddiqui NN, Ul Haq A, Siddiqui OA, Khan R, et al. DNA methyltransferase 1, 3a, and 3b expression in hepatitis C associated human hepatocellular carcinoma and their clinicopathological association. Tumour Biol. 2016. doi:10.1007/s13277-016-4941-1

26.

Shi W, Huang W, Chen Y, et al. Low expression of PIDD is associated with cell proliferation and apoptosis in hepatocellular carcinoma. Tumour Biol. 2016. doi:10.1007/s13277-015-4556-y

27.

Chen W, Chen L, Cai Z, et al. Overexpression of annexin A4 indicates poor prognosis and promotes tumor metastasis of hepatocellular carcinoma. Tumour Biol. 2016. Jul;37(7):9343-55

28.

Li Y, Li Y, Tang R, et al. Discovery and analysis of hepatocellular carcinoma genes using cDNA microarrays. J Cancer Res Clin Oncol. 2002;128:369–79.CrossRefPubMed

29.

Ribarska T, Ingenwerth M, Goering W, et al. Epigenetic inactivation of the placentally imprinted tumor suppressor gene TFPI2 in prostate carcinoma. Cancer Genomics Proteomics. 2010;7:51–60.PubMed

30.

Witte I, Foerstermann U, Devarajan A, et al. Protectors or traitors: the roles of PON2 and PON3 in atherosclerosis and cancer. J Lipids. 2012;2012:342806.CrossRefPubMedPubMedCentral

31.

Ross ME, Zhou X, Song G, et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood. 2003;102:2951–9.CrossRefPubMed

32.

Kang H, Chen IM, Wilson CS, et al. Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood. 2010;115:1394–405.CrossRefPubMedPubMedCentral

33.

Draganov DI, Stetson PL, Watson CE, et al. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem. 2000;275:33435–42.CrossRefPubMed

Title: Downregulation of paraoxonase 3 contributes to aggressive human hepatocellular carcinoma progression and associates with poor prognosis
Authors: Yuepeng Jin
Qiang Li
Junjun Qiu
Xiufen Zhao
Chunxiao Zheng
Shixu Lv
Yongyu Bai
Yunfeng Shan
Le-chi Ye
Publication date: 01-10-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 10/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-5247-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2016

Armillaridin induces autophagy-associated cell death in human chronic myelogenous leukemia K562 cells

Rab23 activities and human cancer—emerging connections and mechanisms

G protein pathway suppressor 2 (GPS2) acts as a tumor suppressor in liposarcoma

Sperm-associated antigen 9 (SPAG9) promotes the survival and tumor growth of triple-negative breast cancer cells

Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU/L

miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes

Keynote webinar | Spotlight on antibody–drug conjugates in cancer